Skip to main content
. Author manuscript; available in PMC: 2011 Jun 15.
Published in final edited form as: Clin Cancer Res. 2010 Jun 1;16(12):3226–3231. doi: 10.1158/1078-0432.CCR-10-0321

Fig. 4.

Fig. 4

Fraction of sera in early (I/II) and late (III/IV) stage NSCLC with a positive level of CFH autoantibody in the microarray. The cutoff points for positivity are as described in the legend to Fig. 3. For comparison, the proportion of sera in each group defined as positive from a visual assessment of immunoblots is shown.